Table 2.

Multivariable analysis for association with OS^*

Covariate	Statistics	HR	95% CI	P-value
ECOG-PS				<0.0001
	1 vs 0	1.606	1.203 – 2.145	0.0013
	>1 vs 0	2.768	1.724 – 4.445	<0.0001
	NA vs 0	1.762	1.215 – 2.555	0.0028
WBC count (× 1000 cells/mm3)	9.8 vs 6.2§	1.066	0.952 – 1.193	0.2696
Visceral metastasis	Yes vs No	1.291	1.012 – 1.647	0.0396
BMI	29.4 vs 24.2§	0.701	0.585 – 0.834	0.0001
Ethnicity				<0.0001
	Not Hispanic/Latino, White	Reference	-	-
	Not Hispanic/Latino, Black	0.217	0.053 – 0.888	0.0336
	Hispanic/Latino	2.152	1.400 – 3.306	0.0005
	Other	0.110	0.016 – 0.775	0.0267
	Unknown	0.466	0.218 – 0.999	0.0498
Prior perioperative chemotherapy	Yes vs No	1.143	0.793 – 1.648	0.4734
Number of cycles	3–5 vs 6–9	1.016	0.775 – 1.332	0.9081

Abbreviations: BMI: body mass index; CI: confidence interval; ECOG-PS: Eastern Cooperative Oncology Group-Performance Status; HR: hazard ratio; NA: not available; OS: overall survival; WBC: white blood cells.

^*Cox multivariate regression analysis stratified by platinum type (cisplatin or carboplatin);

^§The two values are, respectively, the 3^rd and 1^st quartiles of the variable distribution.

• No significant interactions were observed with type of platinum (p=0.09) and “completed planned chemotherapy” (p=0.56).
• Comparison of 4 vs 6 cycles (p=0.57) and 3–5 vs 6 vs 7–9 (p=0.87) yielded no significant differences for OS.